NDC 0310-1730 – Fasenra
Benralizumab 30 mg/mL · Injection, Solution · Subcutaneous
Product NDC0310-1730
Product details
- Brand name
- Fasenra
- Generic name
- Benralizumab
- Labeler
- AstraZeneca Pharmaceuticals LP
- Dosage form
- Injection, Solution
- Route
- Subcutaneous
- Marketing category
- BLA · BLA761070
- Marketed since
- November 14, 2017
- Listing expires
- December 31, 2027
- Pharmacologic class
- Interleukin-5 Receptor alpha-directed Cytolytic Antibody
Active ingredients
- Benralizumab 30 mg/mL
Package NDC codes (2)
| Package NDC | Description | Since |
|---|---|---|
| 0310-1730-30 | 1 SYRINGE, GLASS in 1 CARTON (0310-1730-30) / 1 mL in 1 SYRINGE, GLASS | Nov 14, 2017 |
| 0310-1730-85 sample | 1 SYRINGE, GLASS in 1 CARTON (0310-1730-85) / 1 mL in 1 SYRINGE, GLASS | Nov 14, 2017 |
Recalls mentioning this NDC
- D-0028-2026 Oct 22, 2025 · Class II
Lack of Assurance of Sterility: